Venlafaxine is indicated for the treatment of depression, including depression with associated anxiety, in hospitalized patients.
Treatment of anxiety or Generalized Anxiety Disorder (GAD), including long-term treatment.
The effectiveness of Venlafaxine in long term use for GAD has been evaluated for up to 6 months in controlled clinical trials.
For prevention of relapse of an episode of depression or for prevention of the recurrence of new depressive episodes.
Venlafaxine is indicated for the treatment of Social Anxiety Disorder, also known as Social Phobia, as defined in DSM-IV.
Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of one or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment.
Panic disorder, including prevention of relapse.